We describe a simple, rapid chromatographic method for separating and quantitatively determining sulfisoxazole and 
solution containing 12 mg/L of the internal standard, Nt acetylsulfamethoxazole, in absolute methanol and centrifuged to obtain a clear supernatant solution. This solution is then eluted through a 10-im microparticulate column with a mobile phase of 32/68 (by vol) methanol/sodium acetate buffer (0.01 mol/L, pH 4.7), at a flow rate of 1. The acetylated metabolites of sulfonamides, while possessing no antibacterial activity, have been implicated in many toxic reactions (6) . In particular, kidney damage has been associated with sulfonamide therapy, the result of crystallization of the N4-acetylated metabolites of many sulfonamides.
Sulfisoxazole was initially introduced
to overcome crystalluria because of its high solubility and low pK0 value. The risk of hematuria or crystalluria with sulfisoxazole is low, reported to be 0.2-0.3% (6) and its N4-acetylated metabolite, to ascertain the adequacy of sulfisoxazole therapy, and to be able to predict the likelihood for development of crystalluria.
We describe a rapid, reversed-phase high-pressure liquidchromatographic method for the determination of sulfisoxa- zole and N4-acetylsulfisoxazole in plasma and urine, in which we used an inexpensive, fixed-wavelength detector.
Materials and Methods

Apparatus
We Mobile phase: The mobile phase was methanol/sodium acetate (0.01 mol/L, pH 4.7), 32/68 by vol, prepared by mixing 680 mL of water with 320 inL of methanol, adding 0.6 mL of glacial acetic acid, and adjusting the pH of the solution to 4.7 with 4 mol/L NaOH. The mobile phase was degassed by applying reduced pressure to the stirred solution. We 
Evaluation of the Method
.-acetylsulfisoxazole (50 mg/L of plasma and urine)
. 'r#{216}aredas described above and stored at -10 #{176}C. We *jlyzed with HPLC on six separate occasions over two weeks on days 0 (sample not frozen), 1, 3, 7, 10, and 14. Each plasma urine sample was thawed on the day of analysis. Standard vee plasma and urine were constructed each day as '1ttibed
above, and the sulfisoxazole and N4-acetylsulfisoxazole concentrations of the stability-study solutions were determined by comparing peak-height ratios with those of the standard curve. In addition, for two weeks, four plasma and four urine samples containing sulfisoxazole and N4-acetylsulfisoxazole were left at room temperature (21-23 #{176}C), and four plasma and four urine samples were stored in the refrigerator (4 #{176}C). The samples were assayed on days 0 and 14.
Reproducibility:
We prepared a 5 mg/L solution in plasma and a 50 mg/L solution in urine for both sulfisoxazole and N4-acetylsulfisoxazole and injected each of these into the chromatograph eight times.
Sensitivity:
We Fifty microliters of the concentrated fluid was then injected into the chromatograph.
Recovery:
Aqueous solutions containing 5, 10, 30, 50, 100, and 200 mg/L concentrations of sulfisoxazole and 4-N-acetylsulfisoxazole were prepared and assayed by the method described above for plasma and urine. The results from these standards were compared with those from standard solutions prepared in plasma and urine to determine analytical recovery from the biological fluids.
Results
Representative chromatograms of plasma and urine taken Sulfisoxazole and N4-acetylsulfisoxazole that had been added at 50 mgfL and stored frozen in plasma over two weeks showed no change in concentration when compared with freshly prepared standards at the time of assay. The sulfisoxazole concentration was 49.2 ± 0.6 mg/L (n = 6), and N4-acetylsulfisoxazole was 48.7 ± 0.8 mg/L (n = 6) over the two-week period.
Because these samples were assayed on day 0, 1,3,7, 10, and 14 with no indication of degradation, the variation in the results therefore represents the day-to-day reproducibility (precision) in the assay method.
Plasma and urine samples containing sulfisoxazole and N4-acetylsulfisoxazole left at room temperature or in the refrigerator showed no change in their concentration (n = 4) after two weeks. Both sulfisoxazole and N4-acetylsulfisoxazole were ready for injection onto the HPLC column 30 mm after a blood sample was obtained.
Discussion
Routine clinical assays require speed, accuracy, and specificity, and the method described here meets all of these criteria. It is possible to scale down this method further by using only 10 ML of plasma and 20 ML of internal standard in methanol, provided the plasma concentration is 1 mg/L or more. This is possible because the signal-to-noise ratio is still 7:1 when as little as 3 ng of either sulfisoxazole or N4-acetylsulfisoxazole is injected. This allows the fingertip-puncture or heel-prick method to be used in obtaining plasma samples for assay of both sulfisoxazole and N4-acetylsulfisoxazole. To date, more than 1000 plasma and urine samples have been assayed without significant deterioration of the column, as determined by plate count with a standard consisting of toluene, naphthalene, and benzyl alcohol (prepared by Altex).
To clean the column, a routine 1-h elution with water (1.5 mL/min), followed by elution with methanol (0.3 mL/min) overnight, once a week, is adequate. With repeated injections of plasma and urine samples, the pumping pressure slowly increases under the described procedure. Pressure can be reduced to normal by changing the inlet filter or by cleaning it by sonication for 3 h in nitric acid (500 mL/L), then placing it for 1 h in methanol, either after every 250 samples or when the pressure exceeds 2500 psi at a flow rate of 1.2 mL/min. The method we describe increases the clinician's ability to determine rapidly the adequacy of sulfisoxazole treatment and to resolve potential toxicity problems.
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